hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06290531 id: CEBD-CU-2023-11-12 briefTitle: Different Methods for Reducing Buccal Infiltration Local Anesthesia Injection Pain overallStatus: COMPLETED date: 2022-01-16 date: 2023-09-28 date: 2023-09-28 date: 2024-03-04 date: 2024-03-04 name: Cairo University class: OTHER briefSummary: Local anesthetic injection is considered one of the most annoying dental procedures. The use of topical anesthesia is considered a routine procedure in the dental clinic especially for children. However, the taste and application procedure of the topical gel may not be pleasant for all children.
Ballard et al., 2019, mentioned in their systematic review the efficacy of the Buzzy device for pain management during needle-related procedures, they concluded that the use of the device may be promising. Ghaderi et al., 2013, evaluated the effect of cooling the injection site on pain perception before infiltration of local anesthetics. They found that cooling the injection site before infiltration of local anesthetics in the buccal mucosa for 1 min, reduced pain perceived by pediatric patients. conditions: Dental Caries in Children studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE maskingDescription: The statistician was only blinded for data analysis. But it was not feasible to blind the participant, investigator or the outcome assessor due to the nature of the study. count: 96 type: ACTUAL name: Buzzy device (cold and vibration) name: Buzzy device (vibration only) name: precooling name: Flavored Benzocaine topical anesthetic gel 20% measure: Patient reported pain during needle injection measure: Child behaviour during needle injection measure: Heart rate measure: Oxygen saturation measure: Child and parent satisfaction sex: ALL minimumAge: 6 Years maximumAge: 12 Years stdAges: CHILD facility: Pediatric Dentistry and Dental Public Health, Faculty of Dentistry, Cairo University city: Cairo zip: 11559 country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06290518 id: PROBIFERT P051 briefTitle: Modulation of Reproductive Microbiota by Ligilactobacillus Salivarius CECT5713 overallStatus: COMPLETED date: 2020-09-01 date: 2023-05-03 date: 2024-01-29 date: 2024-03-04 date: 2024-03-04 name: Biosearch S.A. class: INDUSTRY name: Hospital San Carlos, Madrid name: Universidad Complutense de Madrid briefSummary: The objective of the project is to elucidate if the oral administration of Ligilactobacillus salivarius CECT5713 is capable of improving the rates of term pregnancies in couples with infertility problems of unknown cause. On the other hand, the project is aimed to detect microbiological, immunological and hormonal markers that allow the identification of couples in which the administration of the strain could be particularly effective. This is a randomized, double-blind, parallel-group controlled nutritional intervention study. The intervention (Ligilactobacillus salivarius CECT5713 or placebo) will be performed during the 6 months prior to the fertility treatment and during the first IVF cycle (estimated 1-2 months). In case of pregnancy, the woman will continue the treatment until 12 weeks of gestation. conditions: Infertility Unexplained studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Parallel Assignment Volunteers are classified into 2 groups. All women in the probiotic group consume (oral route) a daily capsule with \~50 mg of freeze-dried probiotic (9.5 log10 CFU of L. salivarius CECT5713; excipient: maltodextrin). All women in the placebo group consume (oral route) a daily capsule with \~50 mg of maltodextrin. primaryPurpose: BASIC_SCIENCE masking: TRIPLE maskingDescription: Triple (Participant, Care Provider, Investigator) Only one person of the collaborator that provides the capsules (Biosearch Life) know the correspondecs between each reference (one reference per each subject) and the arm (probiotic or placebo). The codes are blinded for the participant, the care provider and the investigator. whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 72 type: ACTUAL name: Ligilactobacillus salivarius CECT5713 name: Placebo measure: Successful pregnancies measure: Modification of the vaginal microbiota measure: Vaginal immunomodulation sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Biosearch S.A.U. city: Granada zip: 18004 country: Spain lat: 37.18817 lon: -3.60667 facility: Hospital Clínico San Carlos city: Madrid zip: 28040 country: Spain lat: 40.4165 lon: -3.70256 facility: Universidad Complutense de Madrid city: Madrid zip: 28040 country: Spain lat: 40.4165 lon: -3.70256 hasResults: False
nctId: NCT06290492 id: AHMU-tDCS-insomnia briefTitle: Clinical Efficacy and Mechanism of High Definition tDCS Based on dmPFC in the Intervention of Chronic Insomnia overallStatus: RECRUITING date: 2023-05-01 date: 2023-12-30 date: 2024-11-01 date: 2024-03-04 date: 2024-03-04 name: WANG KAI class: OTHER briefSummary: To investigate the intervention effect of transcranial direct current stimulation (tDCS) on subjective and objective insomnia symptoms and daytime function of chronic insomnia patients. conditions: Chronic Insomnia conditions: Transcranial Direct Current Stimulation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 45 type: ESTIMATED name: transcranial direct current stimulation name: sham transcranial direct current stimulation measure: subjective sleep quality assessed by the PSQI measure: subjective sleep quality assessed by the ISI measure: daytime sleepiness assessed by the FFS measure: daytime sleepiness assessed by the ESS measure: objective sleep quality assessed by the PSG measure: emotional symptoms assessed by the HAMA measure: emotional symptoms assessed by the HAMD sex: ALL minimumAge: 15 Years maximumAge: 65 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Anhui Medical University status: RECRUITING city: Hefei state: Anhui country: China name: Kai Wang, PhD role: CONTACT phone: +86-0551-62923704 email: wangkai1964@126.com name: Chengjuan Xie role: CONTACT phone: +8615656989777 email: xie_chengjuan@126.com lat: 31.86389 lon: 117.28083 hasResults: False
nctId: NCT06290479 id: 20358 briefTitle: A Three-Group Study to Examine the Efficacy of the Air up® Drinking System at Improving Hydration and Associated Health Outcomes overallStatus: RECRUITING date: 2024-02-15 date: 2024-06-30 date: 2024-06-30 date: 2024-03-04 date: 2024-03-04 name: air up GmbH class: INDUSTRY name: Citruslabs briefSummary: A randomized, controlled trial evaluating the air up® drinking system's impact on hydration and health outcomes. Participants will use air up® with Peach, Orangeade, or unscented pods and their effects on drinking habits, and health outcomes will be assessed over 12 weeks. conditions: Water Intake studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) primaryPurpose: OTHER masking: QUADRUPLE maskingDescription: Masking: Triple (Participant, Care Provider, Investigator) whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 50 type: ESTIMATED name: Air Up® Peach Pod name: Air Up® Orangeade Pod measure: Change in Hydration Habits and Health Outcomes as Measured by the Water Intake Questionnaire and the Hydration-Related Quality of Life Scale measure: Blood Biomarkers sex: ALL minimumAge: 18 Years maximumAge: 50 Years stdAges: ADULT facility: Citruslabs status: RECRUITING city: Santa Monica state: California zip: 90404 country: United States name: Patrick Renner, MSc role: CONTACT email: hello@citruslabs.com lat: 34.01945 lon: -118.49119 hasResults: False
nctId: NCT06290466 id: FCN-437c-CP-004 briefTitle: Clinical Study on Pharmacokinetics of FCN-437c Capsule and Its Effect on QT Interval in Healthy Subjects overallStatus: COMPLETED date: 2022-11-11 date: 2023-02-08 date: 2023-02-08 date: 2024-03-04 date: 2024-03-04 name: Ahon Pharmaceutical Co., Ltd. class: OTHER briefSummary: This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical trial in healthy subjects.In healthy subjects, 300mg and 400mg FCN-437c capsules were taken orally for a single time. C-QTc effect model was used to evaluate the influence of blood concentration on QT interval, and the pharmacokinetic characteristics and safety of FCN-437c were also evaluated.Based on the C-QTc effect model, this study quantitatively analyzed the relationship between ΔΔQTcF and blood concentration, and evaluated the upper limit of 90% bilateral confidence interval of ΔΔQTcF corresponding to the geometric mean of Cmax at clinically relevant dose of FCN-437c capsule.
This study was carried out in the order of dose from low to high. After the administration of the low-dose group (300mg) and the safety assessment on the fourth day after administration, the study of the high-dose group (400mg) was decided through comprehensive evaluation. conditions: Advanced Breast Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 18 type: ACTUAL name: Low dose group name: High dose group measure: ΔΔQTcF measure: adverse events measure: Physical examination measure: Axillary temperature measure: blood pressure measure: pulse measure: Ecg monitoring and electrocardiogram measure: laboratory examination measure: Plasma concentration and pharmacokinetic parameters measure: Plasma concentration and pharmacokinetic parameters measure: Plasma concentration and pharmacokinetic parameters measure: Plasma concentration and pharmacokinetic parameters measure: Plasma concentration and pharmacokinetic parameters measure: Plasma concentration and pharmacokinetic parameters measure: Plasma concentration and pharmacokinetic parameters measure: Plasma concentration and pharmacokinetic parameters measure: Plasma concentration and pharmacokinetic parameters sex: ALL minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT facility: Peking University Third Hospital city: Beijing state: Beijing zip: 100191 country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06290453 id: AOGR briefTitle: The Regulatory Role of miRNA 27 Follistatin Like Protein-1 Gene in Multiple Scelerosis overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-03 date: 2026-03 date: 2024-03-04 date: 2024-03-04 name: Assiut University class: OTHER briefSummary: Multiple sclerosis (MS) is a neurodegenerative disease characterized by demyelination of the central nervous system. Young women between the ages of 20 and 40 are primarily targeted by this disabling disorder. Till now there are no sufficient mechanisms to explain the pathophysiology of multiple sclerosis. conditions: Multiple Sclerosis studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 60 type: ESTIMATED name: micro RNA 27- FLP1 gene expression name: The Expanded Disability Status Scale (EDSS) name: Electrophysiological assessment: name: MRI examination MRI brain: measure: • To measure the levels of miR-27 expression and its target gene (FSTL1) in progressive MS and relapsing-remitting multiple sclerosis (RRMS) patients. measure: To correlate the levels of expression of miR-27 expression and its target gene (FSTL1) relative to the severity of symptoms of MD patients. sex: FEMALE minimumAge: 20 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
nctId: NCT06290440 id: 28/NDGD-HDDD briefTitle: MEdication Counselling Models for Outpatient oRal antIcoaguLation acronym: MEMORIAL overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2025-12 date: 2026-12 date: 2024-03-04 date: 2024-03-06 name: Gia Dinh People Hospital class: OTHER briefSummary: The goal of this clinical trial is to investigate whether telepharmacy-led counselling can improve medication adherence, knowledge, and hospitalisation/mortality compared with pharmacist-led counselling in adult outpatients taking oral anticoagulants. conditions: Anticoagulants; Circulating, Hemorrhagic Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 360 type: ESTIMATED name: Telepharmacy-led counselling name: Pharmacist-led counselling measure: Medication adherence measure: Knowledge of oral anticoagulants measure: All-cause hospitalisation measure: VTE-related hospitalisation measure: Bleeding-related hospitalisation measure: All-cause mortality measure: VTE-related mortality measure: Bleeding-related mortality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06290427 id: COMPAR-K briefTitle: Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney (COMPAR-K) acronym: COMPAR-K overallStatus: RECRUITING date: 2024-02-01 date: 2024-06 date: 2024-12 date: 2024-03-04 date: 2024-03-04 name: Azienda Ospedaliera Universitaria Integrata Verona class: OTHER briefSummary: The Urology Unit of AOUI Verona proposes a clinical study aimed at a preliminary evaluation of postoperative complications specifically focused on robotic partial nephrectomy (RAPN) procedures using three currently available platforms:
3. surgery with the Versius platform. conditions: Renal Carcinoma studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 45 type: ESTIMATED name: DaVinci RAPN name: Hugo RAS RAPN name: Versius® RAPN measure: Number of participants with postoperative complications measure: Number of participants with moderate to major postoperative complications measure: Number of participants with major postoperative complications measure: Overall duration of the surgery measure: Number of intraoperative complications measure: Type of intraoperative complications measure: Number of intraoperative technical malfunctions measure: Type of intraoperative technical malfunctions measure: Estimated Blood Loss measure: Postoperative hospitalization measure: Postoperative pain measure: Positive Surgical Margins measure: Serum Creatinine dosage for renal function assessment measure: Estimated Glomerular Filtration Rate for renal function assessment measure: Time taken for platform related timings measure: Procedure-related costs sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Urology Unit, AOUI Verona status: RECRUITING city: Verona state: VR zip: 37126 country: Italy name: Alessandro AA Antonelli, MD role: CONTACT phone: +39 0458127701 email: alessandro.antonelli@aovr.veneto.it name: Unità Ricerca Clinica role: CONTACT phone: +39 0458122844 email: unita.ricerca.clinica@aovr.veneto.it lat: 45.4299 lon: 10.98444 hasResults: False
nctId: NCT06290414 id: FDASU-Rec IM 112318 briefTitle: The Accuracy of Infrared Thermographic Imaging for Assessment of Periodontal Status overallStatus: RECRUITING date: 2023-11-30 date: 2024-03-30 date: 2024-07-30 date: 2024-03-04 date: 2024-03-04 name: Ain Shams University class: OTHER briefSummary: The diagnosis and differentiation between periodontal diseases are currently based on the measuring and interpretation of full-mouth clinical and radiographic criteria. Thermography is a modern non-invasive imaging method in which the infrared radiation emitted by an object allows the mapping and analysis of the exact temperature distribution on the surface of the object. The produced thermal images correlate with variations in local blood supply and tissue metabolism. Thus, suggested to be a useful rapid and non-invasive tool for the diagnosis of periodontal diseases. However, the validity of this tool compared to standard tools should be evaluated. conditions: Periodontal Diseases studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 45 type: ESTIMATED name: infrared thermal camera measure: Determine the agreement of thermographic images for diagnosis of periodontal diseases measure: The temperature ranges for healthy periodontium, gingivitis and periodontitis sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Faculty of dentistry Ain Shams University status: RECRUITING city: Cairo country: Egypt name: Shrouk N. Elboray, BDS role: CONTACT phone: +201065433857 email: shrouk.elboraay@dent.asu.edu.eg name: Mahetab M. AbdalWahab, lecturer role: CONTACT phone: +201115554490 email: mahetabmohamed@dent.asu.edu.eg name: Ola M. Ezzatt, professor role: PRINCIPAL_INVESTIGATOR lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06290401 id: 2023-0671 briefTitle: A Socio-ecological Approach for Improving Self-management in Adolescents With SCD acronym: SC-Thrive overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2028-01-31 date: 2028-06-30 date: 2024-03-04 date: 2024-03-04 name: Children's Hospital Medical Center, Cincinnati class: OTHER name: Nemours Children's Health System name: Emory University name: Children's Hospital of Philadelphia briefSummary: The goal of this clinical trial is to evaluate the impact of SCThrive (a behavioral self-management intervention) on patient activation, self-management behaviors, daily functioning, and emergency room visits in 260 adolescents and young adults with sickle cell disease (SCD) ages 13-21 receiving care at 1 of 4 pediatric SCD clinics.
Researchers will compare outcomes for participants who receive SCThrive and participants who receive uniform standard care (SCHealthED which = standard of care plus SCD educational text messages) to see if there are differences in patient activation, self-management behaviors, daily functioning, and emergency room visits. conditions: Anemia, Sickle Cell studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants will be allocated to SCThrive or SCHealthED (uniform standard care) using a randomized block design for age group (13-17 years of age or 18-21 years of age) with a predefined block size of 4. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Investigator and Outcomes assessors will not know the condition to which participants have been randomized. whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 310 type: ESTIMATED name: SCThrive name: SCHealthED measure: Patient Activation measure: Self-Management Behaviors measure: Daily Functioning measure: Emergency Room (ER) Visits measure: Self-Management Skills measure: Health-related quality of life sex: ALL minimumAge: 13 Years maximumAge: 21 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06290388 id: 23ME-01473-CLIN-001 briefTitle: Study of 23ME-01473 in Patients With Advanced Solid Malignancies overallStatus: RECRUITING date: 2024-03-07 date: 2026-06-30 date: 2026-06-30 date: 2024-03-04 date: 2024-03-22 name: 23andMe, Inc. class: INDUSTRY briefSummary: This is a first-in-human open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of 23ME-01473 given by intravenous infusion in participants with advanced solid cancers who have progressed or are intolerant of available standard therapies. conditions: Solid Tumor studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 82 type: ESTIMATED name: 23ME-01473 measure: Phase 1:Incidence and severity of dose-limiting toxicities (DLTs) measure: Phase 1: Incidence and severity of adverse events (AEs) measure: Phase 1 Incidence and severity of serious adverse events (SAEs) measure: ORR based on investigator assessment against RECIST 1.1 criteria measure: Phase 1: Prevalence and incidence of antidrug antibodies (ADA) to 23ME-01473 measure: Phase 1: Objective response rate (ORR) measure: Duration of response (DoR) measure: Disease Control Rate (DCR) measure: Progression free survival (PFS) measure: Time of maximum serum concentration (Tmax) following a single dose of 23ME-01473 measure: Area under the concentration-time curve from zero to the last measurable concentration (AUClast) following a single dose of 23ME-01473 measure: Last measurable serum concentration (Clast) following a single dose of 23ME-01473 measure: Area under the concentration-time curve from zero extrapolated to infinity (AUCinf) following a single dose of 23ME-01473 measure: Terminal half-life (T1/2) following a single dose of 23ME-01473 measure: Maximum serum concentration (Cmax) following multiple doses of 23ME-01473 measure: Time of maximum serum concentration (Tmax) following multiple doses of 23ME-01473 measure: Area under the concentration-time curve from time zero to the end of the dosing interval (AUCtau) following multiple doses of 23ME-01473 measure: Serum concentration at the end of the dosing interval (Ctau) following multiple doses of 23ME-01473 measure: Terminal half-life (T1/2) following multiple doses of 23ME-01473 sex: ALL minimumAge: 18 Years maximumAge: 110 Years stdAges: ADULT stdAges: OLDER_ADULT facility: START Center for Cancer Care status: RECRUITING city: San Antonio state: Texas zip: 78229 country: United States lat: 29.42412 lon: -98.49363 hasResults: False
nctId: NCT06290375 id: HSK21542-T-202 briefTitle: A Study of HSK21542 in a Peritoneal Dialysis Pruritus Population. overallStatus: NOT_YET_RECRUITING date: 2024-03-08 date: 2024-03-08 date: 2025-04-11 date: 2024-03-04 date: 2024-03-04 name: Xizang Haisco Pharmaceutical Co., Ltd class: INDUSTRY briefSummary: This is a two- stage study. Stage I is a multicenter, open-label trial；Stage II was a multi-center, randomized, double-blind, placebo-controlled trial. About 250 maintenance peritoneal dialysis patients with moderate or above pruritus are planned to be enrolled. conditions: Pruritus studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 250 type: ESTIMATED name: HSK21542 tablet name: Placebo measure: Proportion of subjects with an improvement of ≥ 4points from baseline in the weekly average of the daily Worst Itch Numeric Rating Scale (WI-NRS) after 12 weeks of treatment. measure: Change from baseline in subjects' quality of life (evaluated using the Skindex-10 scale ) after 12 weeks of treatment. measure: Change from baseline in subjects' quality of life (evaluated using the 5-D itch scale) after 12 weeks of treatment. sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False